December 22, 2022
|
Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD
|
|
December 1, 2022
|
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
|
|
November 22, 2022
|
Outlook Therapeutics® to Present at the BTIG Ophthalmology Day
|
|
October 28, 2022
|
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
|
|
September 27, 2022
|
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
|
|
September 26, 2022
|
Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
|
|
September 7, 2022
|
Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference
|
|
August 30, 2022
|
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
|
|
August 15, 2022
|
Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD
|
|
August 10, 2022
|
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
|
|